The Company strategy of MediClin is a model of success

Offenburg, May 23, 2012 – In his speech delivered at today’s annual general meeting of MEDICLIN Aktiengesellschaft in Frankfurt, Frank Abele, CEO, has underlined, that MediClin will adhere to the present strategy of the Company.

“We offer an integrated medical care, cross-sectors, close to patients’ homes with high medical quality and the results of our treatments and therapies are disclosed to everybody in a transparent and public way in our quality reports,” he said and added; “We have our emphasis on specific medical fields which are growth areas due to demographic and civilisation-related developments and we will again invest in internal growth by increasing our capacity and to make use of cost reduction potentials.”

Good start in the new financial year
In the first three months of the new financial year, MediClin achieved sales of EUR 125.4 mill. which is EUR 5.4 mill. or 4.5 % above the comparative period of the previous year. The Group operating result for the first quarter of 2012 was EUR -1.2 mill. Adjusted by an aperiodic release of provisions for budget risks in the amount of EUR 1.1 mill., which was included in the previous year’s figure, the Group operating result was EUR 0.5 mill. higher than the figure achieved in the previous year. Clearly improved has the financial result due to a refinancing of the loans of the insurance companies. This effect also let to an overall result on previous year’s level of EUR -2.0 mill.

Cooperation with Asklepios is well on track
An analysis of the common potentials available between MediClin and Asklepios has started at Group level, as well as discussions about location-specific cooperation between the facilities of both holding companies.
MediClin expects that there will be additional growth potential in this area because there are only a few locations where the range of services offered by both groups overlap. Overall, the Management Board expects an increase in sales in the current financial year and a solid development of results, insofar as the framework conditions in the industry and the referral behaviour of the coverage providers do not seriously change in 2012.

The annual general meeting of MediClin agreed to the proposed nominations to the supervisory board. It confirmed the appointment by court order of Stephan Leonhard, it re-elected Dr. Jochen Messemer and it nominated Dr. Ulrich Wandschneider to be a member of the supervisory board, effective June 1st, 2012. Furthermore the supervisory board proposed Dr. Ulrich Wandschneider to become chairman of the supervisory board as soon as he assumes is mandate.
At the annual meeting almost 89 per cent of MediClin’s share capital was represented. All items on the agenda which are subject to voting were passed by 99.99% except one item which was passed by 99.45%.

About MediClin AG (Ticker: MED; WKN: 659 510)
MediClin AG is a nation-wide clinic operator and large provider of services in the area of Psycho- and Neuro-sciences as well as Orthopaedic. With 34 clinics and 7 nursing care facilities and 11 Medizinische Versorgungs-zentren (medical care units) in 11 federal states MediClin has a total capacity of approximately 8,100 beds. MediClins’ facilities include acute care clinics, i.e., general hospitals, special treatment facilities, specialised hospitals and clinics for post-acute treatment and medical rehabilitation. MediClin has approximately 8,300 employees.